Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-811X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer ; volume:15 ; number:1 ; day:8 ; month:12 ; year:2017 ; pages:1-14 ; date:12.2017
Cell communication and signaling ; 15, Heft 1 (8.12.2017), 1-14, 12.2017
- Klassifikation
-
Biowissenschaften, Biologie
- Urheber
-
Ferrari, Nicoletta
- Beteiligte Personen und Organisationen
-
Granata, Ilaria
Capaia, Matteo
Piccirillo, Marina
Guarracino, Mario Rosario
Venè, Roberta
Brizzolara, Antonella
Petretto, Andrea
Inglese, Elvira
Morini, Martina
Astigiano, Simonetta
Amaro, Adriana Agnese
Boccardo, Francesco
Balbi, Cecilia
Barboro, Paola
SpringerLink (Online service)
- DOI
-
10.1186/s12964-017-0206-x
- URN
-
urn:nbn:de:1111-201802094567
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ferrari, Nicoletta
- Granata, Ilaria
- Capaia, Matteo
- Piccirillo, Marina
- Guarracino, Mario Rosario
- Venè, Roberta
- Brizzolara, Antonella
- Petretto, Andrea
- Inglese, Elvira
- Morini, Martina
- Astigiano, Simonetta
- Amaro, Adriana Agnese
- Boccardo, Francesco
- Balbi, Cecilia
- Barboro, Paola
- SpringerLink (Online service)
Ähnliche Objekte (12)
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
PTP1B regulates lymphocytes responses androgen deprivation
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
PTP1B regulates lymphocytes responses androgen deprivation
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
PTP1B regulates lymphocytes responses androgen deprivation